Pluristem Therapeutics PT Raised to $3.50 at Jefferies Group (PSTI)
Jefferies Group hoisted their price target on shares of Pluristem Therapeutics (NASDAQ:PSTI) from $3.00 to $3.50 in a research note issued on Friday, American Banking News.com reports. Jefferies Group’s price objective points to a potential downside of 11.17% from the stock’s previous close.
Separately, analysts at MLV Capital raised their price target on shares of Pluristem Therapeutics from $4.50 to $6.00 in a research note to investors on Tuesday, January 21st. They now have a “buy” rating on the stock.
Shares of Pluristem Therapeutics (NASDAQ:PSTI) traded up 4.79% on Friday, hitting $3.94. The stock had a trading volume of 235,453 shares. Pluristem Therapeutics has a one year low of $2.47 and a one year high of $4.63. The stock’s 50-day moving average is $3.90 and its 200-day moving average is $3.40. The company’s market cap is $235.9 million. Pluristem Therapeutics also was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 665,204 shares, a decrease of 22.8% from the December 31st total of 816,571 shares. Based on an average trading volume of 781,095 shares, the days-to-cover ratio is currently 0.9 days. Approximately 1.2% of the company’s shares are short sold.
Pluristem Therapeutics Inc (NASDAQ:PSTI) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.